Global Allergy Treatment Market 2023-2029

Global Allergy Treatment Market 2023-2029

Allergies are a number of conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. Allergies can cause a variety of symptoms such as a runny nose, sneezing, itching, rashes, swelling, or asthma. The global allergy treatment market is anticipated to increase by USD 12.1 billion till 2029 at an average annual growth of 6.2 percent as per the latest market estimates.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global allergy treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the treatment, dosage form, indication, distribution channel, and region. The global market for allergy treatment can be segmented by treatment: anti-allergy drugs, immunotherapy. Globally, the anti-allergy drugs segment made up the largest share of the allergy treatment market. Allergy treatment market is further segmented by dosage form: oral, nasal, others. The oral segment captured the largest share of the market in 2022. Based on indication, the allergy treatment market is segmented into: eye allergy, skin allergy, food allergy, rhinitis, asthma, others. According to the research, the rhinitis segment had the largest share in the global allergy treatment market. On the basis of distribution channel, the allergy treatment market also can be divided into: hospitals pharmacies, retail pharmacies, online sales, others. The retail pharmacies segment held the largest revenue share in 2022. Allergy treatment market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Globally, North America made up the largest share of the allergy treatment market.

Market Segmentation

By treatment: anti-allergy drugs, immunotherapy

By dosage form: oral, nasal, others

By indication: eye allergy, skin allergy, food allergy, rhinitis, asthma, others

By distribution channel: hospitals pharmacies, retail pharmacies, online sales, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides a detailed analysis of several leading allergy treatment market vendors that include AbbVie Inc. (Allergan plc), ALK-Abello A/S, Allergy Therapeutics PLC, Boehringer Ingelheim International GmbH, Dermapharm Holding SE, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, LETI Pharma, S.L.U., Sanofi S.A., Stallergenes Greer Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

To analyze and forecast the market size of the global allergy treatment market.
To classify and forecast the global allergy treatment market based on treatment, dosage form, indication, distribution channel, region.
To identify drivers and challenges for the global allergy treatment market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global allergy treatment market.
To identify and analyze the profile of leading players operating in the global allergy treatment market.
Why Choose This Report

Gain a reliable outlook of the global allergy treatment market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.